2021 World Conference on Lung Cancer (Posters)-FP04. A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017

FP04. A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017

Back to course

Video Transcription

Video Summary

A multicenter phase 1b2 study evaluated the combination of Imprime PGG and pembrolizumab in patients with advanced stage non-small cell lung cancer. Imprime is a beta-glucan that enhances immune cell killing and activates antigen-presenting cells and T-cells crosstalk. The phase 1b determined the recommended phase 2 dose of Imprime, while the phase 2 aimed to determine progression-free survival. Of the 35 enrolled patients, 9 were in phase 1b and the rest in phase 2. Imprime at a dose of 4 mg/kg every 3 weeks was recommended for the phase 2 study. Treatment-related adverse events were mostly related to Imprime. Efficacy outcomes were better in the phase 1b, possibly due to patient population differences. The combination did not improve patient outcomes overall.

Asset Subtitle

Muhammad Furqan

Meta Tag

Speaker Muhammad Furqan

Topic Immunotherapy (Phase II/III Trials)

Keywords

Imprime PGG

pembrolizumab

non-small cell lung cancer

beta-glucan

phase 2 study